- Home
- PRTA vs NXP Comparison
PRTA vs NXP Comparison
Compare PRTA & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- NXP
- Stock Information
- Founded
- PRTA 2012
- NXP 1992
- Country
- PRTA Ireland
- NXP United States
- Employees
- PRTA N/A
- NXP N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- NXP Trusts Except Educational Religious and Charitable
- Sector
- PRTA Health Care
- NXP Finance
- Exchange
- PRTA Nasdaq
- NXP Nasdaq
- Market Cap
- PRTA 802.8M
- NXP 702.9M
- IPO Year
- PRTA N/A
- NXP N/A
- Fundamental
- Price
- PRTA $13.41
- NXP $14.75
- Analyst Decision
- PRTA Buy
- NXP
- Analyst Count
- PRTA 7
- NXP 0
- Target Price
- PRTA $57.67
- NXP N/A
- AVG Volume (30 Days)
- PRTA 448.2K
- NXP 70.0K
- Earning Date
- PRTA 11-12-2024
- NXP 01-01-0001
- Dividend Yield
- PRTA N/A
- NXP 4.04%
- EPS Growth
- PRTA N/A
- NXP N/A
- EPS
- PRTA N/A
- NXP 0.54
- Revenue
- PRTA $133,350,000.00
- NXP N/A
- Revenue This Year
- PRTA $46.28
- NXP N/A
- Revenue Next Year
- PRTA N/A
- NXP N/A
- P/E Ratio
- PRTA N/A
- NXP $26.81
- Revenue Growth
- PRTA N/A
- NXP N/A
- 52 Week Low
- PRTA $12.31
- NXP $12.91
- 52 Week High
- PRTA $41.55
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- PRTA 43.50
- NXP 47.43
- Support Level
- PRTA $12.31
- NXP $14.68
- Resistance Level
- PRTA $14.28
- NXP $15.08
- Average True Range (ATR)
- PRTA 0.98
- NXP 0.16
- MACD
- PRTA 0.00
- NXP -0.01
- Stochastic Oscillator
- PRTA 33.73
- NXP 19.85
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.